If you work anywhere near brand strategy, market access, or evidence planning, you’ve encountered QALY, sometimes explicitly, sometimes indirectly. You may have seen it as a “cost per QALY” figure in a value assessment, embedded inside an economic model, or referenced during internal pricing or portfolio discussions. Even if the term itself wasn’t used, the logic almost certainly was.
QALY exists because healthcare decisions require comparison. Not comparison of molecules or mechanisms, but comparison of health outcomes across different diseases, populations, and treatment approaches. When one therapy extends survival and another primarily improves symptoms, decision-makers need a way to evaluate both within a common framework. QALY is one of the few tools designed specifically for that purpose.
This article explains what QALY actually is, how it is calculated, and where it is reported or used in practice. The goal is not to defend QALY or criticize it, but to make it understandable enough that you can interpret it correctly when it appears, and recognize when it is shaping decisions even if it isn’t named.
What QALY Actually Measures
A Quality-Adjusted Life Year combines how long people live and how well they live into a single metric.
The concept is simple: one year of life lived in perfect health equals one QALY. If health is less than perfect, that year is weighted downward. The weight applied is called a utility value, typically on a scale where 1 represents perfect health and 0 represents death. Some frameworks allow negative values for health states considered worse than death, but that’s not essential to understanding the basics.
Mathematically, QALY is calculated as:
Time spent in a health state × utility of that health state
The utility value does not come from a clinician’s judgment or a trial endpoint. It usually comes from standardized quality-of-life instruments (such as EQ-5D) that are converted into preference-based scores using population-level valuation studies. This is important: utilities reflect how health states are valued, not just how patients feel.
How QALY is Calculated
Let’s make this explicit.
Imagine two treatment options for the same condition: Treatment A (standard of care) and Treatment B (new therapy).
Step 1: Estimate survival
Based on clinical data and modeling:
- Patients on Treatment A live an average of 4 years
- Patients on Treatment B live an average of 5 years
So Treatment B provides 1 additional life year.
Step 2: Estimate quality of life (utility)
Now estimate average quality-of-life during those years:
- Utility on Treatment A: 0.65
- Utility on Treatment B: 0.75
These utilities already reflect symptom burden, side effects, and overall functioning.
Step 3: Calculate total QALYs
For Treatment A:
-
4 years × 0.65 = 2.6 QALYs
For Treatment B:
-
5 years × 0.75 = 3.75 QALYs
Step 4: Calculate incremental QALYs
-
3.75 − 2.6 = 1.15 incremental QALYs
That number, 1.15 QALYs gained, is what feeds into most downstream value analyses. It tells you that, when you account for both survival and quality of life, Treatment B delivers the equivalent of a little more than one additional year in perfect health compared with Treatment A.
Everything else you see built on QALY, cost-effectiveness, thresholds, scenario analysis—starts from this basic calculation, scaled across populations and time horizons.
Where You Actually See QALY Reported
QALY is not reported in one consistent place or format. Where you encounter it depends almost entirely on market and audience. If you expect to see QALY everywhere, you’ll miss it. If you know where to look, it’s hard to ignore.
In markets with formal health technology assessment processes, QALY is reported explicitly as part of cost–utility analysis. In these settings, QALY appears in the economic model sections of submissions and in assessment reports as total QALYs and incremental QALYs, typically alongside incremental costs. You will not see QALY presented as a standalone figure. It is always embedded in a model and supported by documentation explaining how utility values were sourced, how survival was extrapolated beyond observed data, and how uncertainty was handled. When QALY results are challenged in these reviews, the debate is rarely about the arithmetic itself; it is about whether the assumptions behind the QALY estimates are credible.
In the United States, QALY reporting is more fragmented. There is no single national authority that requires QALY-based submissions, so QALY most often appears in independent value assessments, peer-reviewed cost–utility analyses, and payer-facing economic models prepared for specific discussions. In these contexts, QALY is typically reported as incremental QALYs and cost per QALY over long time horizons. At the same time, many external-facing materials deliberately avoid QALY language, even when the underlying analysis exists. As a result, you can be influenced by QALY-based conclusions without ever seeing the term appear on a slide.
Internally, QALY is reported most often in decision-support materials, not public documents. You may encounter it in pricing corridor discussions, portfolio prioritization decks, scenario analyses, or early asset valuation work. In these settings, QALY functions as a translation tool, converting heterogeneous clinical endpoints, durations, and quality-of-life effects into a common measure of health gain so trade-offs can be examined explicitly. It often appears as incremental QALYs by scenario, by population, or by time period, paired with commentary explaining which assumptions drive the result.
The key point is this: QALY does not need to be visible to be influential. By the time a strategy reaches an external audience, QALY-based modeling has often already shaped which scenarios are considered viable, which prices are viewed as defensible, and which evidence gaps matter most.
Why QALY is Controversial
QALY attracts criticism for several reasons, and you should be aware of them when interpreting results.
First, utilities are preference-based and often derived from general population samples rather than patients. This raises questions about whether the values reflect lived experience. Second, QALY treats one unit of health gain as equivalent regardless of who receives it, which some argue fails to capture equity considerations. Third, QALY results are highly sensitive to modeling assumptions, especially around long-term outcomes and quality-of-life persistence.
None of these critiques mean QALY is unusable. They mean QALY must be interpreted with context. A QALY estimate is not an observed fact; it is a modeled outcome built on explicit assumptions. Understanding those assumptions is more important than focusing on the headline number.
What QALY is and is Not
QALY is not
- a patient experience metric. It incorporates quality-of-life, but it does so through preference weights that may not fully capture individual experiences.
- a standalone decision rule. No responsible system uses QALY in isolation without considering clinical need, uncertainty, feasibility, and broader context.
QALY is a way to make trade-offs visible. It forces clarity about how much health benefit is being generated, over what time horizon, and at what cost. When used properly, it makes disagreements explicit rather than hidden.
Why This Matters for You
Whether or not you ever publish a QALY figure, you are likely already working within a QALY-shaped world. Understanding how QALY is calculated and where it appears allows you to read value assessments critically, ask better questions of models, and recognize when conclusions hinge on assumptions rather than evidence.
QALY doesn’t replace judgment—but it does structure it. And that is why it continues to show up, explicitly or implicitly, across healthcare decision-making.